<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="15365">Acetylsalicylic acid</z:chebi> inhibits <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> production and reduces the risk of vascular occlusive events by 20% to 25% </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="9588">Ticlopidine</z:chebi> inhibits <z:chebi fb="13" ids="16761">ADP</z:chebi>-dependent platelet aggregation and reduces the same risk by 30% to 35%, but produces some adverse effects </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="37941">Clopidogrel</z:chebi> is a ticlopidin-related antiplatelet drug, with the same mechanism of action; it reduces the expression of the <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> IIb/IIIa, the fibrinogen receptor on the platelet surface </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="37941">Clopidogrel</z:chebi> has the same clinical efficacy of ticlopidin and has a decreased incidence of adverse effects </plain></SENT>
<SENT sid="4" pm="."><plain>The effect of one daily dose of 75 mg of <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> on platelet function in 90 subjects was evaluated; 41 with <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> and 49 with cerebral <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Before treatment and after 6 and 12 weeks, <z:mp ids='MP_0001914'>bleeding</z:mp> time and fibrinogen plasma concentration were also evaluated </plain></SENT>
<SENT sid="6" pm="."><plain>There was a reduction in 5-microM <z:chebi fb="13" ids="16761">ADP</z:chebi>-induced platelet aggregation of 38%+/-27% at 6 weeks and 44%+/-29% at 12 weeks in patients with <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>; 35%+/-41%, 29%+/-59% in the cerebral <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> group; and 36%+/-36% and 35%+/-49% in the total group </plain></SENT>
<SENT sid="7" pm="."><plain>Reduction of 20 microg/mL collagen-induced platelet aggregation was not significant in any group </plain></SENT>
<SENT sid="8" pm="."><plain>Plasma fibrinogen levels did not vary during treatment </plain></SENT>
<SENT sid="9" pm="."><plain><z:mp ids='MP_0001914'>Bleeding</z:mp> time was significantly prolonged in <z:hpo ids='HP_0000001'>all</z:hpo> studied groups </plain></SENT>
<SENT sid="10" pm="."><plain>There were no hemorrhagic complications; only digestive discomfort in less than 3% of patients </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="37941">Clopidogrel</z:chebi> efficiently reduces <z:chebi fb="13" ids="16761">ADP</z:chebi>-induced platelet aggregation and prolongs <z:mp ids='MP_0001914'>bleeding</z:mp> time and is a safe and efficacious antiplatelet drug </plain></SENT>
</text></document>